Darolutamide meets primary endpoint in Phase III ARANOTE trial
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
Pfizer advances development of once-daily formulation of oral GLP-1 receptor agonist danuglipron
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson's disease
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
GSK and CureVac to restructure collaboration into new licensing agreement
- Details
- Category: GlaxoSmithKline
![GlaxoSmithKline GlaxoSmithKline](/images/logo/gsk.png)
Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases.
Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](/images/logo/astrazeneca.png)
Sipavibart is an investigational long-acting antibody designed to provide COVID-19 protection for immunocompromised patients who often do not respond adequately to vaccination alone and remain at high risk of serious outcomes from COVID-19.
Berlin Center for Gene and Cell Therapies kicked off in Berlin
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
Bayer receives Breakthrough Therapy designation in China for BAY 2927088
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
More Pharma News ...
- GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies
- Pfizer's LORBRENA® CROWN study shows majority of patients with ALK-positive advanced lung cancer living beyond five years without disease progression
- BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease cell therapy candidate bemdaneprocel
- Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
- AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030
- Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline
- U.S. FDA approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a one-time gene therapy for adults with Hemophilia B